Enhanced absorption of nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects

20Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: This pharmacokinetic (PK) study was designed to investigate the maximum intranasal insulin dose that could be achieved by repeated doses in a single nostril of a nasal spray of recombinant regular human insulin 1% in combination with cyclopentadecalactone (CPE-215) 2%, a compound that enhances absorption of molecules across mucous membranes (Nasulin™, CPEX Pharmaceuticals, Inc.). Method: A nine-period crossover study of 8 healthy, nonsmoking subjects (ages 18-50, body mass index <33 kg/m2, weight >70 kg) were studied. In a fasted state, subjects were randomly given 25, 50, and 75 U in a single nostril on the first day and randomly given 50, 75, and 100 U doses utilizing both nostrils on two subsequent days. After a 45-minute PK assessment, subjects were given a meal. To determine the mechanism of enhanced absorption in a single nostril, a second study utilizing 24 subjects under similar conditions received 25 U, placebo (P) that included CPE-215 plus 25 U, and 50 U in a single nostril. Results: Single nostril administration revealed enhanced absorption with maximum concentrations (Cmax) of 13, 65, and 96 μU/ml for the 25, 50, and 75 U doses, respectively. Dual nostril administration in two cohorts resulted in Cmax of 31/42, 65/52, and 88/79 μU/ml for the 50, 75, and 100 U, respectively. In the second cohort, Cmax was 23, 19, 56 μU/ml for the 25, P + 25, and 50 U doses, respectively. Conclusions: Repeated dosing in a single nostril resulted in enhanced absorption; this was not due to the increased CPE-215 but to the increased insulin administered. © Diabetes Technology Society.

Cite

CITATION STYLE

APA

Stote, R., Miller, M., Marbury, T., Shi, L., & Strange, P. (2011). Enhanced absorption of nasulinTM, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. Journal of Diabetes Science and Technology, 5(1), 113–119. https://doi.org/10.1177/193229681100500116

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free